CAP ’13 – THE Pathologists’ Meeting – October 13 – 16, 2013™
HomeVirtual CatalogLearningSpecial EventsConnection Café & ExhibitsGeneral InfoTravel & HotelExhibitors
Learning

Courses by Topic


Courses by Day


Faculty Index

AP122  Treatment Implication of ER-Positive and HER2-Positive Breast Cancer—The Critical Role of Pathologists

Tuesday, October 15
10:30–11:30 AM
1.25 CME/SAM CREDITS

CAP SAMs Practice-Based Learning and Improvement

Breast cancer is a disease with significant clinical diversity, necessitating an individualized approach to its management. Of central importance to this decision-making is the evaluation of the predictive markers ER, PgR, and HER2 that are routinely utilized to help define treatment. Given the role of these predictive markers in determining therapy, assay results must be as accurate as possible. Various clinical, pathologic, and technical factors can affect the accurate testing of ER and HER2; knowing their presence and their roles in affecting the ER and HER2 results are critical for pathologists reporting these test results. Using cases of ER and HER2 testing as examples, the presenters will illustrate important issues encountered in correct interpretation of ER and HER2 in daily practice. Following this session, participants may complete a related online self-assessment module, available at cap.org through December 31, 2013.

You will learn to:

Faculty
David G. Hicks, MD, FCAP
Ping Tang, MD, PhD, FCAP

 

 

 

 

Register Now Course Materials